509 / 1851
Korean phase II trial
•
Cisplatin
–
Weekly 40 mg/m
2
weekly x 6 cycles
–
3-weekly 75 mg/m
2
x 3 cycles
•
104 patients, Stage IIB-IVA
•
Results
–
Compliance (weekly 86%, 3-weekly 93%,
p
> 0.05)
–
G3-4 neutropenia (weekly 39%, 3-weekly 23%,
p
= 0.03
)
–
5-y OS (weekly 67%, 3-weekly 89%,
p
= 0.03
)
Ryu SY, et al. Int J Radiat Oncol Biol Phys. 2011